Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Annu Rev Med. 2010;61:187-98. doi: 10.1146/annurev.med.050908.132031.
Avian influenza H5N1 viruses that have spread to a number of countries in Asia, the Middle East, and Africa have the potential to cause a pandemic. The most effective public health intervention strategy is to combine preventive vaccination with nonpharmaceutical intervention strategies and enhanced surveillance activities. H5N1 vaccines are poorly immunogenic even at high doses; an adjuvant is needed for enhancement of immunogenicity and for dose-sparing. Lack of effective, yet safe, adjuvants is the limiting factor for candidate vaccines that utilize egg-dependent or egg-independent manufacturing technologies. Hence, developing novel adjuvants is crucial for pandemic influenza vaccine development. Although the use of antiviral drugs is also an important public health countermeasure for preventing and treating influenza, the emergence of drug-resistant strains of avian H5N1 viruses underscores the need to develop not only new drugs but other novel preventive and therapeutic strategies such as vaccines.
已传播至亚洲、中东和非洲多个国家的 H5N1 禽流感病毒有可能引发大流行。最有效的公共卫生干预策略是将预防接种与非药物干预策略和加强监测活动相结合。即使高剂量使用,H5N1 疫苗的免疫原性也很差;需要佐剂来增强免疫原性和节省剂量。缺乏有效且安全的佐剂是利用基于鸡蛋或非鸡蛋生产技术的候选疫苗的限制因素。因此,开发新型佐剂对于大流行性流感疫苗的开发至关重要。尽管使用抗病毒药物也是预防和治疗流感的重要公共卫生措施,但禽流感 H5N1 病毒耐药株的出现突出表明,不仅需要开发新药,还需要开发其他新型预防和治疗策略,如疫苗。